WO2009158719A3 - Methods and compositions for treating disorders - Google Patents

Methods and compositions for treating disorders Download PDF

Info

Publication number
WO2009158719A3
WO2009158719A3 PCT/US2009/049106 US2009049106W WO2009158719A3 WO 2009158719 A3 WO2009158719 A3 WO 2009158719A3 US 2009049106 W US2009049106 W US 2009049106W WO 2009158719 A3 WO2009158719 A3 WO 2009158719A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
treating disorders
treating
disorders
Prior art date
Application number
PCT/US2009/049106
Other languages
French (fr)
Other versions
WO2009158719A2 (en
Inventor
Magdalene M. Moran
Howard Ng
Amy Ripka
Manfred Weigele
Dennis Underwood
Original Assignee
Hydra Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hydra Biosciences, Inc. filed Critical Hydra Biosciences, Inc.
Publication of WO2009158719A2 publication Critical patent/WO2009158719A2/en
Publication of WO2009158719A3 publication Critical patent/WO2009158719A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Compounds and compositions for treating TRPA1 mediated disorders are described herein.
PCT/US2009/049106 2008-06-27 2009-06-29 Methods and compositions for treating disorders WO2009158719A2 (en)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US7640608P 2008-06-27 2008-06-27
US7641108P 2008-06-27 2008-06-27
US7640908P 2008-06-27 2008-06-27
US7644408P 2008-06-27 2008-06-27
US7630908P 2008-06-27 2008-06-27
US7644108P 2008-06-27 2008-06-27
US7640208P 2008-06-27 2008-06-27
US61/076,309 2008-06-27
US61/076,444 2008-06-27
US61/076,411 2008-06-27
US61/076,406 2008-06-27
US61/076,409 2008-06-27
US61/076,402 2008-06-27
US61/076,441 2008-06-27

Publications (2)

Publication Number Publication Date
WO2009158719A2 WO2009158719A2 (en) 2009-12-30
WO2009158719A3 true WO2009158719A3 (en) 2010-04-29

Family

ID=41445391

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/049106 WO2009158719A2 (en) 2008-06-27 2009-06-29 Methods and compositions for treating disorders

Country Status (1)

Country Link
WO (1) WO2009158719A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011009824A (en) 2009-03-23 2012-01-25 Glenmark Pharmaceuticals Sa Fused pyrimidine-dione derivatives as trpa1 modulators.
EA201190138A1 (en) 2009-03-23 2013-05-30 Гленмарк Фармасьютикалс, С.А. FUROPYRIMIDINDION DERIVATIVES AS TRPA1 MODULATORS
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
ES2424340T3 (en) 2009-03-23 2013-10-01 Glenmark Pharmaceuticals S.A. Isothiazole-pyrimidinedione derivatives as modulators of TRPA1
CA2820448A1 (en) 2010-12-20 2012-06-28 Glenmark Pharmaceuticals, S.A. 2-amino-4-arylthiazole compounds as trpa1 antagonists
CA2836856A1 (en) 2011-06-13 2012-12-20 Glenmark Pharmaceuticals, S.A. Treatment of respiratory disorders using trpa1 antagonists
WO2012176105A1 (en) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist
US20140107113A1 (en) 2011-06-22 2014-04-17 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and a beta-2 agonist
EP2736513A1 (en) * 2011-07-25 2014-06-04 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and a steroid
CA2857109A1 (en) 2011-12-05 2013-06-13 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
MX354014B (en) 2012-06-08 2018-02-08 Glenmark Pharmaceuticals Sa Amides of 2-amino-4-arylthiazole compounds and their salts.
JP2016537322A (en) 2013-10-15 2016-12-01 グレンマーク ファーマシューティカルズ， エセ．アー． Pharmaceutical composition comprising a TRPA1 antagonist and an analgesic
WO2016042501A1 (en) 2014-09-16 2016-03-24 Glenmark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
TW202210472A (en) 2020-06-05 2022-03-16 美商奇奈特生物製藥公司 Inhibitors of fibroblast growth factor receptor kinases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089206A2 (en) * 2004-03-13 2005-09-29 Irm Llc Modulators of ion channel trpa1
WO2007073505A2 (en) * 2005-12-22 2007-06-28 Hydra Biosciences, Inc. Trpa1 inhibitors for treating pain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089206A2 (en) * 2004-03-13 2005-09-29 Irm Llc Modulators of ion channel trpa1
WO2007073505A2 (en) * 2005-12-22 2007-06-28 Hydra Biosciences, Inc. Trpa1 inhibitors for treating pain
US20070219222A1 (en) * 2005-12-22 2007-09-20 Hydra Biosciences Methods and compositions for treating pain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MATT PATRUS ET AL.: "A role of TRPAI in mechanical hyperalgesia is revealed by pharmacological inhibition", MOLECULAR PAIN, vol. 3, no. 40, 17 December 2007 (2007-12-17), pages 1 - 8 *

Also Published As

Publication number Publication date
WO2009158719A2 (en) 2009-12-30

Similar Documents

Publication Publication Date Title
WO2009158719A3 (en) Methods and compositions for treating disorders
WO2009120810A3 (en) Neurodegenerative disorders
WO2011016840A3 (en) Methods and compositions for treating trinucleotide repeat disorders
WO2008128072A3 (en) Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
WO2009059304A3 (en) Compounds for treating abnormal cellular proliferation
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
WO2010077740A3 (en) Novel antiviral compounds, compositions, and methods of use
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2009108860A3 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
EP2331088A4 (en) Compositions and methods for treating psychiatric disorders
EP2170309A4 (en) Methods and compositions for treating disorders
WO2006071960A3 (en) Compositions and methods of treating cell proliferation disorders
WO2010151799A3 (en) Compounds for modulating rna binding proteins and uses therefor
WO2010151797A3 (en) Compounds for modulating rna binding proteins and uses therefor
EP2281058A4 (en) Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders
EP2282735A4 (en) Compounds, compositions and methods for making the same
WO2009014891A3 (en) Increasing plant vigor
WO2008027600A3 (en) Imatinib compositions
WO2010123759A9 (en) Compositions and methods for treating burns
WO2007140205A3 (en) Methods of treating fibrosis
WO2010017368A3 (en) Methods and compositions for treating anxiety
WO2011079307A3 (en) Methods and compositions for treating neurological disorders
WO2013023151A3 (en) Compositions and methods for treating celiac sprue disease
WO2010141956A3 (en) Methods and compositions for the treatment of cancer
WO2012017321A3 (en) Treatment for dyslipidemia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09771250

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09771250

Country of ref document: EP

Kind code of ref document: A2